{"id":"vvn461-ophthalmic-solution-1-0","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target is not publicly disclosed, VVN461 is being developed as a topical ophthalmic agent for phase 3 evaluation. As a 1.0% solution formulation, it is intended for direct ocular surface application to address inflammatory or degenerative eye conditions. The specific mechanism likely involves modulation of immune or inflammatory mediators at the ocular surface.","oneSentence":"VVN461 is an ophthalmic solution designed to treat ocular surface disease by modulating inflammatory pathways in the eye.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:57.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ocular surface disease (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT07136805","phase":"PHASE3","title":"A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","status":"NOT_YET_RECRUITING","sponsor":"VivaVision Biotech, Inc","startDate":"2025-10-01","conditions":"Non-infectious Anterior Uveitis","enrollment":152},{"nctId":"NCT06164743","phase":"PHASE2","title":"Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"VivaVision Biotech, Inc","startDate":"2024-01-11","conditions":"Inflammation","enrollment":91},{"nctId":"NCT06906198","phase":"PHASE1","title":"Pharmacokinetics of VVN461 Ophthalmic Solution","status":"COMPLETED","sponsor":"VivaVision Biotech, Inc","startDate":"2023-03-01","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06679153","phase":"PHASE2","title":"A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","status":"COMPLETED","sponsor":"VivaVision Biotech, Inc","startDate":"2023-11-27","conditions":"Anterior Uveitis","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VVN461 Ophthalmic Solution 1.0%","genericName":"VVN461 Ophthalmic Solution 1.0%","companyName":"VivaVision Biotech, Inc","companyId":"vivavision-biotech-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VVN461 is an ophthalmic solution designed to treat ocular surface disease by modulating inflammatory pathways in the eye. Used for Ocular surface disease (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}